Publications
Study highlights the usage of FDA-approved tyrosine kinase inhibitors for treating leukemia patients with neurotrophic receptor tyrosine kinase mutations.
Integrated analysis of RNA-sequencing, proteomics, and phosphoproteomics data indicate doublecortin like kinase 1 (DCLK1) modulates proteins and pathways associated with cell motility in patient-derived pancreatic ductal adenocarcinoma (PDAC) organoids.
UCSF CTD2 scientists developed a multi-faceted testing framework and demonstrate that analysis of protein networks rather than a single gene identifies synthetic lethal candidates. These candidates are reproducible as they are dependent on genetic and cellular context.
p85β regulatory subunit of phosphatidylinositol 3-kinase upregulates tyrosine kinase, AXL, activating p110 subunit to induce PDK1/SGK3 signaling in PIK3R2-amplified ovarian cancer. These findings indicate that targeting AXL with small molecule inhibitors could be a potential therapeutic strategy.
Pages
